Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
In a pooled nonrandomized phase 3 analysis, monthly lerodalcibep reduced LDL-C by about 50% in heterozygous familial hypercholesterolemia, with similar efficacy across LDLR functional variant categories and broad attainment of guideline-bas
Researchers developed and validated integrated polygenic risk scores for eight cardiovascular conditions using data from over 245,000 individuals. These scores demonstrated strong predictive power and improved risk classification, providing
New research comparing diabetes medications reveals GLP-1 receptor agonists lower heart failure hospitalization risk compared to DPP-4 inhibitors, while showing similar risk to SGLT-2 inhibitors in type 2 diabetes patients.
In ARIC, ischemic stroke at age 80 years or older was more often embolic than thrombotic. Atrial fibrillation and left atrial disease explained much of the age effect, and adding embolic factors improved prediction.
In Medicare beneficiaries, ATTR-CM was diagnosed a median 494 days after heart failure and 840 days after loop diuretic initiation, with delays more common in women and patients with several common comorbidities.
In a patient-level meta-analysis of 10,212 Asian and 61,471 non-Asian AF patients, standard-dose DOACs outperformed warfarin more strongly in Asians, with less stroke, major bleeding, and net clinical harm. Standard-dose therapy was favored
In nine U.S. coronary stent PMA trials, minority participants were markedly underrepresented, while women were modestly underrepresented. Site geography and surrounding county demographics predicted minority enrollment, suggesting targeted
The REPRIEVE trial reveals higher heart failure incidence in people with HIV, particularly among women, Black participants in high-income regions, and those with hypertension or obesity. Traditional risk factors, not HIV-specific markers, w
A new study shows that the Burst exercise stress test is more effective than the traditional Bruce protocol in detecting arrhythmias in CPVT patients, leading to better treatment decisions without safety concerns.
Higher midlife cardiorespiratory fitness is associated with longer healthspan, fewer chronic diseases, and extended lifespan in men and women, based on a large observational cohort study linking clinical data to Medicare claims.
Higher CKM syndrome stages correlate with adverse cardiac remodeling and increased heart failure risk in older adults, as shown in the ARIC Study.
Study finds long-term TSH suppression in postmenopausal women with thyroid cancer correlates with poorer cardiovascular health, reduced quality of life, and increased osteoporosis risk compared to controls.
A multi-center study reveals that circulatory support escalation in cardiogenic shock is associated with higher mortality and complications, but certain patient factors can predict successful outcomes.
This study highlights the role of RBM20 truncating variants in arrhythmogenic dilated cardiomyopathy, showing reduced penetrance and milder disease severity compared to pathogenic missense variants and titin truncating variants.
Shorter pre-treatment fibrin clot lysis time independently predicts higher bleeding risk in AF patients on oral anticoagulation, as evidenced by the ARISTOTLE trial.
The PURE study reveals significant global disparities in heart failure incidence and mortality, with hypertension as the leading modifiable risk factor, highlighting the need for targeted prevention and treatment strategies.
The PRAETORIAN-DFT trial demonstrates that omitting defibrillation testing in subcutaneous ICD implantation, guided by the PRAETORIAN score, is non-inferior to traditional testing for first-shock efficacy, reducing procedural risks without
A structured exercise program combining mobility therapy and resistance training in ECMO patients proved feasible and safe, with longer session times correlating with better functional performance.
A study finds bradykinin modestly contributes to blood pressure reduction with sacubitril/valsartan in chronic heart failure, highlighting ANP’s role in initial effects and bradykinin’s influence during chronic therapy.
A novel sixth-gen hs-cTnT assay with a 13 ng/L threshold safely identified twice as many low-risk MI patients at ED presentation vs fifth-gen assays, achieving >99.5% NPV in multinational validation.
Open language-specific specialty feeds and department pages.